Payment overview · 2025
General Payments
$303.39
14 reported records · 10 companies
Healthcare provider profile · identity verified
Kevin Via, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, SC · NPI 1215340542
Verified facts
What the public records show
CMS Open Payments records show Kevin Via, MD received $303.39 in general payments during 2025 across 14 reported records.
Dexcom, Inc. accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $109.71 | 36.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.94 | 16.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.16 | 7.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.67 | 6.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.88 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.52 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.69 | 5.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.33 | 5.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $15.88 | 5.2% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $14.61 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $303.39 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $109.71 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 374 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 351 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 63 |
| Losartan Potassium | Losartan Potassium | 221 | 70 |
| Omeprazole | Omeprazole | 176 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 47 |
| Lisinopril | Lisinopril | 148 | 45 |
| Metformin Hcl Er | Metformin Hcl | 139 | 48 |
| Trazodone Hcl | Trazodone Hcl | 113 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 38 |
| Gabapentin | Gabapentin | 107 | 38 |
| Metformin Hcl | Metformin Hcl | 103 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 34 |
| Famotidine | Famotidine | 98 | 32 |
| Furosemide | Furosemide | 95 | 31 |
| Spironolactone | Spironolactone | 93 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 29 |
| Eliquis | Apixaban | 76 | 21 |
| Carvedilol | Carvedilol | 73 | 24 |
| Ozempic | Semaglutide | 73 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 27 |
| Montelukast Sodium | Montelukast Sodium | 67 | 23 |
| Allopurinol | Allopurinol | 66 | 19 |
| Simvastatin | Simvastatin | 61 | 20 |
| Tramadol Hcl | Tramadol Hcl | 60 | 14 |
| Januvia | Sitagliptin Phosphate | 58 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 18 |
| Mounjaro | Tirzepatide | 58 | 13 |
| Meloxicam | Meloxicam | 57 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 29 |
| Ezetimibe | Ezetimibe | 50 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 17 |
| Methylprednisolone | Methylprednisolone | 49 | 40 |
| Jardiance | Empagliflozin | 47 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 12 |
| Mirtazapine | Mirtazapine | 42 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 17 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 14 |
| Bupropion Xl | Bupropion Hcl | 37 | 14 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 14 |
| Sertraline Hcl | Sertraline Hcl | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Valsartan | Valsartan | 33 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Rybelsus | Semaglutide | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 12 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 16 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Prednisone | Prednisone | 22 | 16 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Naproxen | Naproxen | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $303.39 · 14 records | Dexcom, Inc. | ABRYSVO, CAPVAXIVE, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, GARDASIL 9, JARDIANCE, Korlym, NEXPLANON, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error